The TB Vaccine Evaluation Group uses the non-human primate (NHP) model to assess the safety, efficacy and immunogenicity of a range of novel vaccines and therapeutics to protect against and treat Tuberculosis, a disease which was responsible for ~1.4 million deaths in 2019.
You will be involved in the analysis of blood samples to measure the mycobacteria-specific cellular immune response at ACDP Containment Levels 2 & 3 using a range of advanced immunoassays including; the ELISPOT assay, flow cytometry to analyse immunological memory and functional markers, polyfunctional T-cell analysis and multiplex bead array technology. You will be also be involved in identifying other opportunities to optimize new methods and technologies for use with archived samples.
You will also be responsible for supervising the ACDP2 & 3 laboratory; maintaining a safe working environment, assessing risks and organizing consumable provisions. There will also be some supervision of junior members of staff.
The successful applicants will be educated to degree level in a relevant subject or equivalent level of experience of working at a similar level in a specialist area. Education to MSc or PhD in an appropriate biological science is desirable.